Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status

Table 3 Comparison of operational characteristics of conventional RBA and our ECL-based assay for human IA

	Radiobinding Assay*	ECL^†Assay
Input Material	Serum or Plasma	Serum or Plasma
Input Volume	5 μL/well (10 μL total)	5 μL/well (30 μL total)
Isotypes Detected	IgA, IgG, IgM	IgG
Detection Agent	Radioactive I¹²⁵-insulin	Non-radioactive anti-human IgG-TAG
Time to Result	4 days	6 hours
Standard Curve	Yes	No
Maximum Reported AS95 ^\|\|	74%	88%
Maximum Reported AUC ^¶ (95%CI ^# )	0.91 (085-0.96)	0.97 (0.92-1.01)

*All information regarding radiobinding assay performance has been collected from the 2010 report by Schlosser et al. [26]. †ECL, Electrochemiluminescence; ||AS95, Sensitivity at 95% specificity ¶AUC, area under the curve, calculated from the ROC curve used to assess the ability of each assay to distinguish between non-diabetic and long-standing diabetic individuals; #CI95, 95% confidence interval

ISSN: 1479-5876